BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT02564718
Inhalation Flow Rate-study
Phase 1
Completed
- Conditions
- Bronchiectasis
- Interventions
- Device: T-326 Inhaler
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT02563197
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Phase 3
Active, not recruiting
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT02562235
- Locations
- 🇩🇪
Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
🇭🇺Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet, Budapest, Hungary
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
Completed
- Conditions
- Prevention and ControlStrokeAtrial Fibrillation
- Interventions
- Drug: Direct Oral Anticoagulant (DOAC)
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 247
- Registration Number
- NCT02559232
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2540
- Registration Number
- NCT02558465
- Locations
- 🇯🇵
Many locations, Multiple Locations, Japan
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
Phase 3
Terminated
- Conditions
- Transcatheter Aortic Valve Replacement
- Interventions
- Drug: Acetylsalicylic Acid (ASA)
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1653
- Registration Number
- NCT02556203
Interaction With HIV Antiretroviral Agents
Phase 1
Completed
- Conditions
- HIV-DDI
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT02556268
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
Completed
- Conditions
- Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT02555059
Russia/Ukraine Suppression of Ovarian Activity Study
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: Gestodene/EE Patch (BAY86-5016)
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 91
- Registration Number
- NCT02550977
Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT02549469
© Copyright 2025. All Rights Reserved by MedPath